Skip to main content
Clinical Trials/NL-OMON31896
NL-OMON31896
Recruiting
Not Applicable

on-invasive markers for colorectal neoplasia A multi-marker approach in screening for colorectal cancer - Non-invasive markers for colorectal neoplasia

Academisch Ziekenhuis Maastricht0 sites410 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
cancer of the large bowel
Sponsor
Academisch Ziekenhuis Maastricht
Enrollment
410
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects who will undergo a colonoscopy.
  • 1\) average\-risk population
  • Employees (50\-65 years of age) from companies participating in the ongoing workplace\-based CRC screening project by colonoscopy have already been included.
  • 2\) high\-risk population
  • Patients with a positive family history of CRC visiting the \*outpatient clinic for hereditary colorectal cancer\* or visiting the endoscopy unit of the MUMC\+ for surveillance colonoscopy will be asked to participate into the study. This population will include patients with hereditary forms of CRC (Lynch syndrome or FAP) as well as patients fulfilling the criteria for familial CRC syndrome: i) ³ 1 first degree relative (FDR) with CRC diagnosed \< 50 year or ii) ³ 2 FDR with CRC diagnosed between 50\-70 year or iii) 1 FDR and 1 second degree relative with CRC diagnosed \< 70 year.
  • 3\) CRC patients
  • Patients diagnosed with CRC, visiting the \*emergency outpatient clinic\* of the Division of Gastroenterology\-Hepatology after the initial diagnosis of CRC and before subsequent therapeutic interventions are started, will be included.
  • Additionally, a subset of patients diagnosed with either oesophageal, gastric or pancreatic cancer will be included at our \*emergency outpatient clinic\* of the Division of Gastroenterology\-Hepatology after initial diagnosis and before subsequent therapeutic interventions are started. We will include 20 patients for each group of non\-colorectal gastrointestinal malignancy.

Exclusion Criteria

  • Individuals will be excluded if:
  • \-younger than 18 years old
  • \-diagnosed with inflammatory bowel disease (Crohn\*s disease or ulcerative colitis)
  • \-diagnosed with major co\-morbidity which may interfere with the outcome of the study (e.g. severe cardiovascular or pulmonary disease, other malignancies)

Outcomes

Primary Outcomes

Not specified

Similar Trials